Connect with us

Tampa biotech enrolls patients for Phase 2 trial

May 20, 2019 - More than 80 patients are enrolled for a Phase 2 clinical trial for AG013, the lead compound in a proposed treatment for oral mucositis from Oragenics (NYSE American: OGEN). There are 61 identified clinical test sites and 48 of them are actively enrolling patients, a news release from the Tampa biotechnology company said. In addition, the World Health Organization has provided Oragenics with the generic name of "dapatifagene navolactibac" for the AG013 compound.

More Zaps Frontpage

The St. Pete Catalyst

The Catalyst honors its name by aggregating & curating the sparks that propel the St Pete engine.  It is a modern news platform, powered by community sourced content and augmented with directed coverage.  Bring your news, your perspective and your spark to the St Pete Catalyst and take your seat at the table.

Email us:

Subscribe for Free

Share with friend

Enter the details of the person you want to share this article with.